The estimated Net Worth of John A Cottingham is at least $69.5 Thousand dollars as of 24 May 2013. John Cottingham owns over 60,000 units of Atyr Pharma Inc stock worth over $69,527 and over the last 16 years John sold LIFE stock worth over $0.
John has made over 14 trades of the Atyr Pharma Inc stock since 2008, according to the Form 4 filled with the SEC. Most recently John exercised 60,000 units of LIFE stock worth $1,831,800 on 24 May 2013.
The largest trade John's ever made was exercising 60,000 units of Atyr Pharma Inc stock on 24 May 2013 worth over $1,831,800. On average, John trades about 10,377 units every 74 days since 2008. As of 24 May 2013 John still owns at least 36,593 units of Atyr Pharma Inc stock.
You can see the complete history of John Cottingham stock trades at the bottom of the page.
John's mailing address filed with the SEC is 5791 VAN ALLEN WAY, , CARLSBAD, CA, 92008.
Over the last 16 years, insiders at Atyr Pharma Inc have traded over $27,288,922 worth of Atyr Pharma Inc stock and bought 966,653 units worth $5,761,237 . The most active insiders traders include James C Blair, Gregory T Lucier, and Craig J Mundie. On average, Atyr Pharma Inc executives and independent directors trade stock every 22 days with the average trade being worth of $34,257. The most recent stock trade was executed by Jill Marie Broadfoot on 31 May 2024, trading 5,000 units of LIFE stock currently worth $8,950.
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation
Atyr Pharma Inc executives and other stock owners filed with the SEC include: